As of Nov 19, 2026, 1 of 2 active firms rate MRVI a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MRVI EPS & revenue forecast
EPS · NEXT QUARTER
$0.01
Range $0.00 – $0.02 · 4 analysts · -17% YoY
Next period, 4 analysts expect Maravai Lifesciences Holdings Inc to earn $0.01 a share (range $0.00 – $0.02), versus $0.01 a year earlier. Full-year consensus is $-0.07, growing to $-0.08 the year after.
REVENUE · NEXT QUARTER
$61.1M
Range $54.2M – $70.0M · 4 analysts · -7% YoY
Revenue is expected to reach $61.1M (range $54.2M – $70.0M), -7.2% year-over-year. Full-year consensus is $214.3M, rising to $224.6M next year.
Top analysts covering Maravai Lifesciences Holdings Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MRVI.
#1
Conor McNamara
RBC Capital · Rank #254
Buy
$5.00-32.2% to target
Overall win rate
34%
+ Follow
#2
Christian Schwab
Craig-Hallum · Rank #348
Buy
$5.00-32.2% to target
Overall win rate
41%
+ Follow
#3
Matthew Sykes
Goldman Sachs · Rank #352
Sell
$4.25-42.4% to target
Overall win rate
38%
+ Follow
#4
Brandon Couillard
Wells Fargo
Buy
$5.50-25.4% to target
Coverage
—
+ Follow
#5
DB
Dan Brennan
UBS
Neutral
$8.00+8.4% to target
Coverage
—
+ Follow
MRVI stock forecast FAQ
What is MRVI's average 12-month price target?+
The 2 active firms with a live target average $7.25 for Maravai Lifesciences Holdings Inc over the next 12 months, ranging from a $8.00 high to a $6.50 low, as of Nov 19, 2026.
Is MRVI stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MRVI?+
The Street-high target is $8.00 (UBS), and the Street-low is $6.50 (Wells Fargo). The average of all 2 active-firm targets is $7.25.
How many active Wall Street firms cover MRVI?+
2 active firms have a recognized rating on Maravai Lifesciences Holdings Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MRVI?+
Among analysts who currently cover MRVI, Conor McNamara of RBC Capital has the strongest overall Quantellect track record (Rank #254). Their current call is Buy with a $5.00 target.
What is Maravai Lifesciences Holdings Inc's projected EPS for next quarter?+
The consensus estimate is $0.01 per share (range $0.00 – $0.02) across 4 analysts. Full-year EPS is projected at $-0.07, rising to $-0.08 the following year.
How much revenue is Maravai Lifesciences Holdings Inc expected to report next quarter?+
Consensus revenue is $61.1M (range $54.2M – $70.0M). Full-year revenue is projected at $214.3M, growing to $224.6M next year.
Have analysts been upgrading or downgrading MRVI lately?+
As of Nov 19, 2026, 1 of 2 active firms rate MRVI a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MRVI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.